BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38228909)

  • 1. CCDC92 promotes podocyte injury by regulating PA28α/ABCA1/cholesterol efflux axis in type 2 diabetic mice.
    Zuo FW; Liu ZY; Wang MW; Du JY; Ding PZ; Zhang HR; Tang W; Sun Y; Wang XJ; Zhang Y; Xie YS; Wu JC; Liu M; Wang ZY; Yi F
    Acta Pharmacol Sin; 2024 May; 45(5):1019-1031. PubMed ID: 38228909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease.
    Zuo F; Wang Y; Xu X; Ding R; Tang W; Sun Y; Wang X; Zhang Y; Wu J; Xie Y; Liu M; Wang Z; Yi F
    Metabolism; 2024 Jan; 150():155724. PubMed ID: 37952690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exendin-4 Ameliorates Lipotoxicity-induced Glomerular Endothelial Cell Injury by Improving ABC Transporter A1-mediated Cholesterol Efflux in Diabetic apoE Knockout Mice.
    Yin QH; Zhang R; Li L; Wang YT; Liu JP; Zhang J; Bai L; Cheng JQ; Fu P; Liu F
    J Biol Chem; 2016 Dec; 291(51):26487-26501. PubMed ID: 27784780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small GTPase Arf6 regulates diabetes-induced cholesterol accumulation in podocytes.
    Hu J; Yang Q; Chen Z; Liang W; Feng J; Ding G
    J Cell Physiol; 2019 Dec; 234(12):23559-23570. PubMed ID: 31206670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease.
    He M; Li Y; Wang L; Guo B; Mei W; Zhu B; Zhang J; Ding Y; Meng B; Zhang L; Xiang L; Dong J; Liu M; Xiang L; Xiang G
    Diabetologia; 2020 Sep; 63(9):1916-1931. PubMed ID: 32588068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes.
    Ducasa GM; Mitrofanova A; Mallela SK; Liu X; Molina J; Sloan A; Pedigo CE; Ge M; Santos JV; Hernandez Y; Kim JJ; Maugeais C; Mendez AJ; Nair V; Kretzler M; Burke GW; Nelson RG; Ishimoto Y; Inagi R; Banerjee S; Liu S; Szeto HH; Merscher S; Fontanesi F; Fornoni A
    J Clin Invest; 2019 Jul; 129(8):3387-3400. PubMed ID: 31329164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevation of JAML Promotes Diabetic Kidney Disease by Modulating Podocyte Lipid Metabolism.
    Fu Y; Sun Y; Wang M; Hou Y; Huang W; Zhou D; Wang Z; Yang S; Tang W; Zhen J; Li Y; Wang X; Liu M; Zhang Y; Wang B; Liu G; Yu X; Sun J; Zhang C; Yi F
    Cell Metab; 2020 Dec; 32(6):1052-1062.e8. PubMed ID: 33186558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclodextrin protects podocytes in diabetic kidney disease.
    Merscher-Gomez S; Guzman J; Pedigo CE; Lehto M; Aguillon-Prada R; Mendez A; Lassenius MI; Forsblom C; Yoo T; Villarreal R; Maiguel D; Johnson K; Goldberg R; Nair V; Randolph A; Kretzler M; Nelson RG; Burke GW; Groop PH; Fornoni A;
    Diabetes; 2013 Nov; 62(11):3817-27. PubMed ID: 23835338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-4645-3p attenuates podocyte injury and mitochondrial dysfunction in diabetic kidney disease by targeting Cdk5.
    Zhang Y; Xia S; Tian X; Yuan L; Gao Y; Liu D; Qi H; Wang S; Liu Z; Li Y; Zhao Z; Liu W
    FASEB J; 2024 May; 38(10):e23668. PubMed ID: 38742811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes.
    Chen D; Liu Y; Chen J; Lin H; Guo H; Wu Y; Xu Y; Zhou Y; Zhou W; Lu R; Zhou J; Wu J
    Eur J Pharmacol; 2021 Jul; 902():174121. PubMed ID: 33901462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired Podocyte Autophagy Exacerbates Proteinuria in Diabetic Nephropathy.
    Tagawa A; Yasuda M; Kume S; Yamahara K; Nakazawa J; Chin-Kanasaki M; Araki H; Araki S; Koya D; Asanuma K; Kim EH; Haneda M; Kajiwara N; Hayashi K; Ohashi H; Ugi S; Maegawa H; Uzu T
    Diabetes; 2016 Mar; 65(3):755-67. PubMed ID: 26384385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of STARD3-mediated cholesterol transport alleviates diabetes-induced podocyte injury by reducing mitochondrial cholesterol accumulation.
    Hu J; Zhu Z; Zhang Z; Hu H; Yang Q
    Life Sci; 2024 Jul; 349():122722. PubMed ID: 38754814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCA1 deficiency-mediated glomerular cholesterol accumulation exacerbates glomerular endothelial injury and dysfunction in diabetic kidney disease.
    Zhang J; Wu Y; Zhang J; Zhang R; Wang Y; Liu F
    Metabolism; 2023 Feb; 139():155377. PubMed ID: 36521550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Podocyte Injury in Diabetic Kidney Disease in Mouse Models Involves TRPC6-mediated Calpain Activation Impairing Autophagy.
    Salemkour Y; Yildiz D; Dionet L; 't Hart DC; Verheijden KAT; Saito R; Mahtal N; Delbet JD; Letavernier E; Rabant M; Karras A; van der Vlag J; Nijenhuis T; Tharaux PL; Lenoir O
    J Am Soc Nephrol; 2023 Nov; 34(11):1823-1842. PubMed ID: 37678257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.
    Pedigo CE; Ducasa GM; Leclercq F; Sloan A; Mitrofanova A; Hashmi T; Molina-David J; Ge M; Lassenius MI; Forsblom C; Lehto M; Groop PH; Kretzler M; Eddy S; Martini S; Reich H; Wahl P; Ghiggeri G; Faul C; Burke GW; Kretz O; Huber TB; Mendez AJ; Merscher S; Fornoni A
    J Clin Invest; 2016 Sep; 126(9):3336-50. PubMed ID: 27482889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
    Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
    Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA-binding proteins tristetraprolin and human antigen R are novel modulators of podocyte injury in diabetic kidney disease.
    Guo J; Lei M; Cheng F; Liu Y; Zhou M; Zheng W; Zhou Y; Gong R; Liu Z
    Cell Death Dis; 2020 Jun; 11(6):413. PubMed ID: 32487989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apelin promotes diabetic nephropathy by inducing podocyte dysfunction via inhibiting proteasome activities.
    Guo C; Liu Y; Zhao W; Wei S; Zhang X; Wang W; Zeng X
    J Cell Mol Med; 2015 Sep; 19(9):2273-85. PubMed ID: 26103809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caspase-11/4 and gasdermin D-mediated pyroptosis contributes to podocyte injury in mouse diabetic nephropathy.
    Cheng Q; Pan J; Zhou ZL; Yin F; Xie HY; Chen PP; Li JY; Zheng PQ; Zhou L; Zhang W; Liu J; Lu LM
    Acta Pharmacol Sin; 2021 Jun; 42(6):954-963. PubMed ID: 32968210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPR43 activation-mediated lipotoxicity contributes to podocyte injury in diabetic nephropathy by modulating the ERK/EGR1 pathway.
    Lu J; Chen PP; Zhang JX; Li XQ; Wang GH; Yuan BY; Huang SJ; Liu XQ; Jiang TT; Wang MY; Liu WT; Ruan XZ; Liu BC; Ma KL
    Int J Biol Sci; 2022; 18(1):96-111. PubMed ID: 34975320
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.